Efficacy of bivalirudin sequential dose therapy in patients with ST-segment elevation myocardial infarction undergoing emergency intervention during the perioperative period

Objective: This study aimed to observe the efficacy and safety of bivalirudin sequential dose therapy in patients with ST-segment elevation myocardial infarction (STEMI) undergoing emergency percutaneous coronary intervention (PCI). Methods: A total of 86 patients that were diagnosed with STEMI and underwent emergency PCI, from January 2012 to March 2017, were retrospectively analyzed. Main observational indexes included in-stent thrombosis rate and incidence of various bleeding events within 30 days postoperatively. Other observational indexes included incidence of major adverse cardiac and cerebrovascular events (MACCE) and thrombocytopenia within 30 days. Results: Enrolled patients had an average age of 62.56±12.97 years old. The percentage of males was 82.6% and percentage of PCI was 97.7%. During the 30 days of follow-up, no patients had in-stent thrombosis. Incidence of total bleeding events, MACCE, and postoperative thrombocytopenia were 3.49%, 2.26%, and 2.26%, respectively. Conclusion: Bivalirudin sequential dose therapy can be safely and effectively applied in patients with STEMI undergoing emergency PCI. This therapy can effectively control perioperative risk of bleeding during emergency PCI, with good anticoagulant effects.